Compare Stocks: CTKB, ALMR, MRVI, and BLFS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMR Alamar Biosciences	$30.80 +0.8%	$28.58	$18.84 ▼ $38.54	$2.14B	N/A	312,791 shs	142,948 shs
BLFS BioLife Solutions	$35.25 -0.8%	$32.25	$17.86 ▼ $38.10	$1.72B	1.91	703,957 shs	344,309 shs
CTKB Cytek Biosciences	$4.70	$4.55	$3.28 ▼ $6.18	$610.91M	1.18	998,160 shs	478,226 shs
MRVI Maravai LifeSciences	$7.32 -0.7%	$6.76	$2.37 ▼ $9.42	$1.90B	0.6	2.47 million shs	1.55 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMR Alamar Biosciences	+0.26%	-7.36%	+12.76%	+48.83%	+3,056,999,900.00%
BLFS BioLife Solutions	-1.09%	-4.49%	+9.26%	+33.32%	+41.89%
CTKB Cytek Biosciences	+0.21%	+1.73%	+9.81%	+14.91%	+19.29%
MRVI Maravai LifeSciences	-0.14%	-11.95%	+14.62%	+46.81%	+212.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMR Alamar Biosciences	$30.80 +0.8%	$28.58	$18.84 ▼ $38.54	$2.14B	N/A	312,791 shs	142,948 shs
BLFS BioLife Solutions	$35.25 -0.8%	$32.25	$17.86 ▼ $38.10	$1.72B	1.91	703,957 shs	344,309 shs
CTKB Cytek Biosciences	$4.70	$4.55	$3.28 ▼ $6.18	$610.91M	1.18	998,160 shs	478,226 shs
MRVI Maravai LifeSciences	$7.32 -0.7%	$6.76	$2.37 ▼ $9.42	$1.90B	0.6	2.47 million shs	1.55 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMR Alamar Biosciences	+0.26%	-7.36%	+12.76%	+48.83%	+3,056,999,900.00%
BLFS BioLife Solutions	-1.09%	-4.49%	+9.26%	+33.32%	+41.89%
CTKB Cytek Biosciences	+0.21%	+1.73%	+9.81%	+14.91%	+19.29%
MRVI Maravai LifeSciences	-0.14%	-11.95%	+14.62%	+46.81%	+212.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMR Alamar Biosciences	2.43	Hold	$31.80	4.16% Upside
BLFS BioLife Solutions	2.18	Hold	$31.38	-11.24% Downside
CTKB Cytek Biosciences	2.33	Hold	$5.56	19.24% Upside
MRVI Maravai LifeSciences	2.00	Hold	$6.25	-15.71% Downside

Current Analyst Ratings Breakdown

Latest CTKB, ALMR, MRVI, and BLFS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	MRVI Maravai LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/11/2026	ALMR Alamar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D+)
8/11/2026	ALMR Alamar Biosciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $32.00
8/11/2026	ALMR Alamar Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$32.00 ➝ $35.00
8/10/2026	BLFS BioLife Solutions	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/7/2026	CTKB Cytek Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.00
8/7/2026	MRVI Maravai LifeSciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$5.50 ➝ $6.50
7/28/2026	BLFS BioLife Solutions	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/27/2026	BLFS BioLife Solutions	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$32.00 ➝ $31.00
7/27/2026	BLFS BioLife Solutions	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$32.00 ➝ $31.00
7/23/2026	BLFS BioLife Solutions	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$30.00 ➝ $31.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMR Alamar Biosciences	$74.21M	28.55	N/A	N/A	$4.51 per share	6.77
BLFS BioLife Solutions	$96.21M	17.95	$0.23 per share	156.87	$8.60 per share	4.11
CTKB Cytek Biosciences	$201.49M	3.01	N/A	N/A	$2.48 per share	1.88
MRVI Maravai LifeSciences	$185.74M	10.37	$0.42 per share	17.63	$1.37 per share	5.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMR Alamar Biosciences	-$29.82M	-$1.96	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BLFS BioLife Solutions	-$4.59M	$1.16	30.43	220.94	N/A	53.29%	2.70%	2.49%	11/5/2026 (Estimated)
CTKB Cytek Biosciences	-$66.54M	-$0.62	N/A	N/A	N/A	-38.98%	-12.40%	-9.17%	11/4/2026 (Estimated)
MRVI Maravai LifeSciences	-$130.77M	-$0.52	N/A	N/A	N/A	-37.07%	-15.70%	-8.17%	11/5/2026 (Estimated)

Latest CTKB, ALMR, MRVI, and BLFS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ALMR Alamar Biosciences	-$0.36	-$0.22	+$0.14	-$0.22	N/A	$29.43 million
8/6/2026	Q2 2026	BLFS BioLife Solutions	$0.0313	$0.91	+$0.8788	$0.91	$27.80 million	$28.47 million
8/6/2026	Q2 2026	MRVI Maravai LifeSciences	-$0.0435	-$0.02	+$0.0235	-$0.08	$48.67 million	$51.44 million
8/5/2026	Q2 2026	CTKB Cytek Biosciences	-$0.0933	-$0.09	+$0.0033	-$0.09	$47.31 million	$48.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMR Alamar Biosciences	N/A	N/A	N/A	N/A	N/A
BLFS BioLife Solutions	N/A	N/A	N/A	N/A	N/A
CTKB Cytek Biosciences	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMR Alamar Biosciences	0.03	11.85	10.23
BLFS BioLife Solutions	N/A	9.69	7.14
CTKB Cytek Biosciences	N/A	4.48	3.86
MRVI Maravai LifeSciences	0.49	4.05	2.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMR Alamar Biosciences	N/A
BLFS BioLife Solutions	93.24%
CTKB Cytek Biosciences	69.46%
MRVI Maravai LifeSciences	50.25%

Insider Ownership

Company	Insider Ownership
ALMR Alamar Biosciences	N/A
BLFS BioLife Solutions	2.20%
CTKB Cytek Biosciences	10.36%
MRVI Maravai LifeSciences	2.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMR Alamar Biosciences	222	69.39 million	N/A	N/A
BLFS BioLife Solutions	440	48.86 million	47.78 million	Optionable
CTKB Cytek Biosciences	500	129.98 million	116.52 million	Optionable
MRVI Maravai LifeSciences	610	259.67 million	253.21 million	Optionable

CTKB, ALMR, MRVI, and BLFS Headlines

Recent News About These Companies

Braidwell LP Sells 1,537,243 Shares of Maravai LifeSciences Holdings, Inc. $MRVI

September 3 at 4:23 AM | marketbeat.com

Headlands Technologies LLC Makes New $1.04 Million Investment in Maravai LifeSciences Holdings, Inc. $MRVI

September 2 at 3:52 AM | marketbeat.com

Maravai LifeSciences (NASDAQ:MRVI) Lowered to Hold Rating by Wall Street Zen

August 29, 2026 | americanbankingnews.com

Maravai LifeSciences (NASDAQ:MRVI) Stock Rating Lowered by Wall Street Zen

August 29, 2026 | marketbeat.com

Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Down - Here's Why

August 28, 2026 | marketbeat.com

Maravai LifeSciences (NASDAQ:MRVI) Trading Down 5.3% - Should You Sell?

August 27, 2026 | marketbeat.com

Maravai LifeSciences (NASDAQ:MRVI) Sets New 52-Week High - Still a Buy?

August 25, 2026 | marketbeat.com

Maravai LifeSciences (NASDAQ:MRVI) Sees Large Volume Increase - Still a Buy?

August 20, 2026 | marketbeat.com

TEM, BNTX, MRVI, RGEN, NVAX stock rallies as Moderna-Merck cancer vaccine clears late-stage trial

August 19, 2026 | msn.com

Maravai LifeSciences (NASDAQ:MRVI) Reaches New 1-Year High - What's Next?

August 19, 2026 | marketbeat.com

Stifel Nicolaus Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)

August 15, 2026 | theglobeandmail.com

Wall Street Zen Upgrades Maravai LifeSciences (NASDAQ:MRVI) to Buy

August 15, 2026 | marketbeat.com

Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI

August 13, 2026 | marketbeat.com

Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

August 8, 2026 | marketbeat.com

Maravai LifeSciences (MRVI) Releases Q2 2026 Earnings: Revenue Beats Estimates and Loss Narrows

August 7, 2026 | quiverquant.comQ

Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Down - Here's What Happened

August 7, 2026 | marketbeat.com

Wells Fargo & Company Issues Positive Forecast for Maravai LifeSciences (NASDAQ:MRVI) Stock Price

August 7, 2026 | marketbeat.com

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

August 7, 2026 | finance.yahoo.com

Maravai LifeSciences Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Maravai LifeSciences Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB, ALMR, MRVI, and BLFS Company Descriptions

Alamar Biosciences NASDAQ:ALMR

$30.80 +0.23 (+0.75%)

As of 04:00 PM Eastern

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. We commercially launched our proprietary instrument, the ARGO High Throughput (“HT”) System in January 2024 and have already experienced rapid adoption, with more than 300 customers across 25 countries and a cumulative installed base of over 100 instruments with an average annual pull-through greater than $400,000 per instrument for the year ended December 31, 2025. The robust performance of our platform is further evidenced in over 100 scientific publications since our commercial launch. Our customers include top global research and academic institutions, biopharmaceutical companies, contract research organizations and service labs. All ten of the top ten biopharma companies by 2024 revenue are customers of Alamar. We are also developing a second proprietary instrument as part of our IVD platform, called the ARGO HT/DX instrument, for which we intend to provide a submission to the FDA for marketing authorization in 2027. We have established multiple multi-million dollar collaborations with renowned research foundations to help support the development of our ARGO HT/DX instrument and the discovery of biomarkers in neurodegenerative disease. Proteins are essential for all life functions and the fundamental molecules behind healthy cellular operations and the causal mechanisms of disease, as illustrated by the fact that a large majority of effective drugs have proteins as targets. Proteomic analysis has great potential to identify “biomarkers” of health, to characterize disturbances in disease, to discover new drug targets, to assess risks and to measure the impact of interventions such as drugs and lifestyle changes. However, the complexity of disease and biology requires analysis of multiple proteins and pathways at once. As a result of this complexity, much of the human proteome has remained unmeasurable or unquantifiable by other proteomic technologies, and true Precision Proteomics has not been possible. Our proprietary and patented NULISA technology addresses these critical limitations, and we believe it is currently the only platform that enables Precision Proteomics. The chemistry underpinning our technology employs a unique sequential purification of immunocomplexes to suppress background noise and enable the detection of low-abundance protein targets in biofluids across large and diverse populations. Our platform is a fully integrated and fully automated proteomic analysis solution and provides scientists with an end-to-end solution to precisely and consistently measure from one to over one hundred low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research, and ultimately, diagnostics. Scientists value our platform because it offers an accessible, easy-to-use and reliable ultra-high sensitivity and multiplexed biomarker analysis of large cohorts of samples. Our current instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is currently available for research use only (“RUO”) applications. It was built to execute our NULISA chemistry in a simple and reproducible workflow for broad biomarker profiling, validation and potential translation into future clinical use. The ARGO HT System facilitates the seamless analysis of large cohorts and clinical research with minimal handling, rapid turnaround times and high data quality. Our initial assay menu focuses on neurology and immunology. We develop a significant portion of our assay panels in close partnership with our customers, who are experts in identifying important protein biomarkers in their respective fields. Our flagship multiplex assay, the CNS Disease Panel 120, provides broad coverage of neurodegeneration pathways. Additionally, our single-plex BD-pTau217 assay can distinctly measure brain-derived-pTau217, which is present in low abundance in blood and is critical for research involving biomarkers for early diagnosis of Alzheimer’s disease. Our assay enables BD-pTau217 quantitation using a small blood sample, offering a noninvasive, economical and convenient alternative to cerebrospinal fluid sample tests or PET scans. We also develop kits for customers to create their own assays, enabling our technology to meet the needs of customers operating in their disease areas of interest. The flexibility of our platform is designed to enable researchers to seamlessly transition from high-plex discovery panels to the development of low-plex diagnostics assays. As a result, our strategy is to continue driving adoption in the targeted discovery and translational markets and subsequently establish a foundation for clinical diagnostics through internal innovation and external collaborations. Ultimately, our platform is designed to support the entire customer journey from discovery to diagnostics, unlocking the full value of precision medicine and early disease detection. We were founded in May 2018 as a Delaware corporation. Our principal executive offices are located in Fremont, California.

BioLife Solutions NASDAQ:BLFS

$35.25 -0.28 (-0.79%)

As of 04:00 PM Eastern

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Cytek Biosciences NASDAQ:CTKB

$4.70 0.00 (0.00%)

As of 04:00 PM Eastern

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Maravai LifeSciences NASDAQ:MRVI

$7.32 -0.05 (-0.68%)

As of 04:00 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTKB, ALMR, MRVI, and BLFS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTKB, ALMR, MRVI, and BLFS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTKB, ALMR, MRVI, and BLFS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB, ALMR, MRVI, and BLFS Company Descriptions

Alamar Biosciences NASDAQ:ALMR

BioLife Solutions NASDAQ:BLFS

Cytek Biosciences NASDAQ:CTKB

Maravai LifeSciences NASDAQ:MRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTKB, ALMR, MRVI, and BLFS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTKB, ALMR, MRVI, and BLFS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTKB, ALMR, MRVI, and BLFS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB, ALMR, MRVI, and BLFS Company Descriptions

Alamar Biosciences NASDAQ:ALMR

BioLife Solutions NASDAQ:BLFS

Cytek Biosciences NASDAQ:CTKB

Maravai LifeSciences NASDAQ:MRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools